Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras
AssigneeThe Scripps Research Institute
InventorsJohn Hood, Brian Eliceiri, David Cheresh
Life of this patent
Estimating the term…
Abstract
The present invention describes methods for modulating angiogenesis in tissues using Raf and/or Ras protein, modified Raf or Ras protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Raf and/or Ras protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Raf and/or Ras protein, or nucleic acids encoding therefor. The invention also describes the use of gene delivery systems for providing nucleic acids encoding for the Raf or Ras protein, or modified forms thereof.
Claims28
An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treating disease conditions by modulating angiogenesis, and wherein said pharmaceutical composition comprises an oligonucleotide having a nucleotide sequence capable of expressing a Raf protein.
A method for modulating angiogenesis in a tissue associated with a disease condition comprising administering to said tissue an angiogenesis modulating amount of a pharmaceutical composition comprising a nucleotide sequence capable of expressing a Raf protein.
A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a gene transfer vector containing a nucleic acid, said nucleic acid having a nucleic acid segment encoding for a Raf protein and a pharmaceutically acceptable carrier or excipient.
A method for modulating angiogenesis in a tissue associated with a disease condition comprising administering to said tissue an angiogenesis modulating amount of a pharmaceutical composition comprising a nucleotide sequence capable of expressing Raf protein, and a nucleotide sequence capable of expressing Ras protein.
Dependencies are inferred from the claim text.